These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23486449)

  • 1. In chemotherapy for lung cancer, sometimes less is more.
    Roeland E; Loprinzi C; Moynihan TJ; Smith TJ; Temel J
    J Natl Compr Canc Netw; 2013 Mar; 11(3):232-5. PubMed ID: 23486449
    [No Abstract]   [Full Text] [Related]  

  • 2. Palliative benefits of chemotherapy treatment in non-small cell lung cancer may be underappreciated.
    J Support Oncol; 2006 Feb; 4(2):61. PubMed ID: 16499116
    [No Abstract]   [Full Text] [Related]  

  • 3. Complexities of quality of life analysis in non-small cell lung cancer.
    Temel J
    J Support Oncol; 2007 Jan; 5(1):30-1. PubMed ID: 17265784
    [No Abstract]   [Full Text] [Related]  

  • 4. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress?
    Buccheri G
    Lung Cancer; 1994 Jul; 11(1-2):115-7. PubMed ID: 7521731
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy for non-small cell lung cancer.
    Carbone DP; Minna JD
    BMJ; 1995 Oct; 311(7010):889-90. PubMed ID: 7580533
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new medication for lung cancer].
    Krankenpfl J; 2005; 43(7-10):227. PubMed ID: 16515296
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy for advanced non-small cell lung cancer.
    Herbst RS; Dang NH; Skarin AT
    Hematol Oncol Clin North Am; 1997 Jun; 11(3):473-517. PubMed ID: 9209907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs in the palliative chemotherapy of advanced non-small-cell lung cancer.
    Malayeri R; Pirker R; Huber H
    Onkologie; 2001 Oct; 24(5):416-21. PubMed ID: 11694767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Das M
    Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy and surgery for operable NSCLC.
    Bradbury PA; Shepherd FA
    Lancet; 2007 Jun; 369(9577):1903-4. PubMed ID: 17544498
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy of advanced non-small cell lung cancer.
    Jassem J
    Ann Oncol; 1999; 10 Suppl 6():77-82. PubMed ID: 10676557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Singh N; Aggarwal AN
    Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
    [No Abstract]   [Full Text] [Related]  

  • 13. Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all.
    Schiller JH; Ramalingam SS
    J Clin Oncol; 2009 Jul; 27(20):3265-7. PubMed ID: 19470911
    [No Abstract]   [Full Text] [Related]  

  • 14. Palliative chemotherapy for non-small cell lung cancer: a measured dose of reality.
    Kalemkerian GP
    J Support Oncol; 2007 Jan; 5(1):27-8. PubMed ID: 17265783
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy for lung cancer.
    Locke I; Gillham CM
    N Engl J Med; 2002 May; 346(19):1498; author reply 1498. PubMed ID: 12000824
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy for advanced non-small-cell lung cancer.
    Walling J
    Respir Med; 1994 Oct; 88(9):649-57. PubMed ID: 7528933
    [No Abstract]   [Full Text] [Related]  

  • 18. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapeutic management of stage IV non-small cell lung cancer.
    Socinski MA; Morris DE; Masters GA; Lilenbaum R;
    Chest; 2003 Jan; 123(1 Suppl):226S-243S. PubMed ID: 12527582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
    Socinski MA
    J Clin Oncol; 2009 Jul; 27(20):3268-70. PubMed ID: 19470913
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.